Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections – Pipeline Review, H2 2017’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections

The report reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Influenza A Virus, H1N1 Subtype Infections therapeutics and enlists all their major and minor projects

The report assesses Influenza A Virus, H1N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Beijing Minhai Biotechnology Co Ltd

BioCryst Pharmaceuticals Inc

Cadila Healthcare Ltd

CEL-SCI Corp

Cilian AG

Cocrystal Pharma Inc

ContraFect Corp

Curevac AG

EpiVax Inc

Etubics Corp

Gemmus Pharma Inc

Genentech Inc

iBio Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kineta Inc

Kyowa Hakko Kirin Co Ltd

Lakewood-Amedex Inc

Medicago Inc

MedImmune LLC

Microbiotix Inc

Mucosis BV

NanoViricides Inc

NewLink Genetics Corp

Novavax Inc

OPKO Health Inc

PeptiDream Inc

Recce Ltd

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Touchlight Genetics Ltd

Vaccibody AS

Vaxart Inc

Vironova AB

Visterra Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Influenza A Virus, H1N1 Subtype Infections - Overview 6

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development 7

Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 21

Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 29

Influenza A Virus, H1N1 Subtype Infections - Drug Profiles 50

Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 182

Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 185

Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 186

Appendix 198

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by AbbVie Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Adimmune Corp, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Akshaya Bio Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Altimmune Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Antigen Express Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cadila Healthcare Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by CEL-SCI Corp, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cilian AG, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by ContraFect Corp, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Curevac AG, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by EpiVax Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Etubics Corp, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Gemmus Pharma Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Genentech Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by iBio Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Johnson & Johnson, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kineta Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Lakewood-Amedex Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Medicago Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by MedImmune LLC, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Microbiotix Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Mucosis BV, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by NanoViricides Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by NewLink Genetics Corp, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Novavax Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by OPKO Health Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by PeptiDream Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Recce Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sanofi, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sanofi Pasteur SA, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Sarepta Therapeutics Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by SK Chemicals Co Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by TechnoVax Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Touchlight Genetics Ltd, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaccibody AS, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vaxart Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Vironova AB, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Pipeline by Visterra Inc, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H2 2017

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H2 2017 (Contd..1), H2 2017

Influenza A Virus, H1N1 Subtype Infections – Dormant Projects, H2 2017 (Contd..2), H2 2017

Influenza A Virus, H1N1 Subtype Infections – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports